Cirrus Healthcare improves upon its best-selling EarPlanes with launch of EP2
COLD SPRING HARBOR, N.Y. — Earlier this year, Cirrus Healthcare Products improved upon what was already one of the leading earplugs on the market with the introduction of EP2 at a suggested retail price of about $10.
Its predecessor, EarPlanes, generated $3 million across total U.S. multi-outlets for the 52 weeks ended July 10, according to IRI, on growth of 3.9%.
"After years of Earplanes user requests for a reusable,softer [earplug] and a safety tether for child safety, Adult and Childrens EP2 was released to the market," Drew O'Connell, CEO Cirrus Healthcare, told Drug Store News. "User experience to date has been very positive."
Cirrus Healthcare is both the pioneer and patented inventor of Earplanes, raising awareness across both consumers groups and doctors that a solution to ear barotrauma was available. "Today, Earplanes is the gold standard in flight protection globally," O'Connell said.
In addition to including a convenient tether, the improved EP2 earplugs are reusable for up to 10 trips.
Goodgut prebiotics gain mass retail distribution
PALO ALTO, Calif. — Greenteaspoon, the team behind Goodgut, on Thursday announced that its clinically-proven line of prebiotic supplements is now available at leading retailers nationwide.
Goodgut products, which work to help stop "leaky gut" and promote digestive health, have been offered through the company's website and on Amazon.com for the past year. Now, customers have the option to pick up Goodgut prebiotics from their local Walgreens, CVS, Vitamin Shoppe or Meijer stores.
"On behalf of the Goodgut science and R&D team, we're thrilled our customers now have the option to shop for our products at leading national chain outlets within their own neighborhoods," stated Robert Wotring, CEO of Greenteaspoon. "We believe that the Goodgut product line has the potential to fundamentally transform people's digestive, as well overall, health and well-being – and we are extremely excited that leading drugstore chains have embraced our breakthrough offering," he said. "The fact that Goodgut is now accessible to individuals via the mass consumer marketplace speaks to the retail segment's growing support for what we believe is a truly evolutionary addition … to the fast-growing prebiotic/probiotic space."
The brand markets multiple formulas designed to help a range of individuals based on their specific digestive profiles and overall gut health needs.
Goodgut Rescue provides rapid help for the sudden onset symptoms of diarrhea, upset stomach, gas and bloating; Goodgut Balance alleviates digestive distress and is designed to help balance daily health; and Goodgut Boost helps to strengthen the immune system.
CHPA advocates for modernized OTC Monograph system
WASHINGTON — The OTC Monograph system that regulates over-the-counter medicines is more than four decades old and in need of modernization, according to Consumer Healthcare Products Association president and CEO, Scott Melville who testified earlier this week in strong support of OTC Monograph reform before the House Energy and Commerce Committee, Subcommittee on Health.
“CHPA member companies produce the vast majority of OTC medicines in our country and provide millions of Americans with safe, effective and affordable therapies to treat and prevent many common ailments and conditions,” Melville said. “The availability of self-care treatment options saves money, reduces burdens on the healthcare system, and keeps consumers active and productive.”
Citing the importance of OTC medicines to consumers and our nation’s healthcare system, Melville emphasized that it is essential for the OTC regulatory structure to promote efficiency, transparency and innovation. To ensure the U.S. Food and Drug Administration is adequately funded and resourced to accomplish this important work, the subcommittee is considering a draft of OTC Monograph reform legislation.
CHPA strongly supports the OTC Monograph system as a balanced framework for regulating OTC medicines containing ingredients with a proven history of safe use. And, as emphasized in the Congressional hearing, CHPA, health professionals and manufacturers in the OTC marketplace support modernization.
“The legislation we are discussing today is incredibly important and, if enacted, will impact the health of nearly every American for decades to come,” Melville said. “It’s the product of months – and even years – of consideration and compromise between many stakeholders,” he said. “We look forward to continuing to work with members of this committee to finalize the text and support its introduction and consideration by the Congress.”